Fingerprint
Dive into the research topics of 'Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer
Christopher R. Garrett, Tanios S. Bekaii-Saab, Theresa Ryan, George A. Fisher, Sally Clive, Petr Kavan, Einat Shacham-Shmueli, Aby Buchbinder, Richard M. Goldberg
Research output: Contribution to journal › Article › peer-review
28
Scopus
citations